Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lumos Pharma Inc (NQ: LUMO )

4.330 +0.020 (+0.46%)
Streaming Delayed Price Updated: 11:53 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lumos Pharma Inc

< Previous 1 2 3 4 Next >
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
From Lumos Pharma, Inc.
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, OB on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, INSI on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Analyst Expectations For Lumos Pharma's Future
Via Benzinga
Lumos Pharma: Q4 Earnings Insights
Via Benzinga
Earnings Preview: Lumos Pharma
Via Benzinga
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
INVESTIGATION ALERT: Halper Sadeh LLC Continues to Investigate MMLP, FSHP, ICCH, and LUMO on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Shareholder Alert: Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
Lumos Pharma and the FDA Align on Final Design for Global, Double-blinded, Placebo-Controlled Phase 3 Trial Evaluating Oral LUM-201 in PGHD 
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
From Lumos Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
From Lumos Pharma, Inc.
Via GlobeNewswire
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
From Lumos Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.